Shares of Venus Remedies rallied 7% on 26 October after the company announced that it had received approval from the Medicines and Healthcare Regulatory Agency (MHRA) in the United Kingdom.

In its regulatory filing, the company said that it had received final approval from MHRA in the UK for its Bleomycin 15,000 IU Powder for Solution for Injection/infusion. The drug was made by its German Subsidiary, Venus Pharm GmbH.

The company said, “This remarkable milestone not only expands the pharma giant’s global presence but also underscores its commitment to advancing cancer care with innovative solution.”

Bleomycin 15,000 IU is a potent medication that contains the active ingredient bleomycin sulphate, which belongs to a group of medicines known as cytostatic drugs that are specifically designed to combat cancer. This class of medications are often referred to as chemotherapy.

The company said that they are proud to hold a total of 15 market authorisations for Bleomycin products across the globe, which is the company’s effort to make it more accessible.

At 3:30 pm, the shares of Venus Pharma closed 1.61% above at Rs 240 on NSE.